NAPLEX Drug Interaction Case Practice Questions with Answers

A NAPLEX Drug Interaction Case involves the clinical evaluation of a patient's medication profile to identify, prevent, and manage harmful interactions between drugs, foods, or disease states. Mastering these cases requires a deep understanding of pharmacokinetics, specifically the Cytochrome P450 (CYP450) enzyme system, and pharmacodynamics, which involves the additive or antagonistic effects of medications at the receptor level. As you prepare for your licensing exam, integrating these concepts with clinical scenarios is essential for ensuring patient safety and therapeutic efficacy.

Concept Explanation

Drug interactions are categorized primarily into pharmacokinetic and pharmacodynamic interactions that can significantly alter the safety and efficacy of a therapeutic regimen. Pharmacokinetic interactions occur when one drug alters the absorption, distribution, metabolism, or excretion (ADME) of another. The most common mechanism involves the induction or inhibition of metabolic enzymes, such as the CYP450 enzyme system. For example, an inhibitor increases the concentration of a substrate, potentially leading to toxicity, while an inducer decreases the concentration, potentially leading to therapeutic failure. You can refine your clinical reasoning by practicing with our NAPLEX Prep hub, which offers comprehensive resources for these complex topics.

Pharmacodynamic interactions occur when drugs have additive, synergistic, or antagonistic effects without changing each other's plasma concentrations. A classic example is the increased risk of bleeding when a patient takes both warfarin and an NSAID; the NSAID inhibits platelet aggregation and causes gastric mucosal damage, which pharmacodynamically enhances the bleeding risk already present from warfarin's vitamin K antagonism. Understanding these relationships is vital, especially when managing high-risk patients, such as those discussed in our NAPLEX Anticoagulation Practice Questions with Answers.

Key areas for NAPLEX focus include:

• CYP450 Inhibitors: G-PACMAN (Grapefruit, Protease inhibitors, Azole antifungals, Cimetidine, Macrolides, Amiodarone, Non-DHP CCBs).
• CYP450 Inducers: PS-PORCS (Phenytoin, Smoking, Phenobarbital, Oxcarbazepine, Rifampin, Carbamazepine, St. John’s Wort).
• P-glycoprotein (P-gp) Interactions: Drugs like digoxin and cyclosporine are common substrates.
• QTc Prolongation: Additive risks with fluoroquinolones, macrolides, and most antipsychotics.
• Serotonin Syndrome: Combining SSRIs, SNRIs, MAOIs, or Triptans.

Solved Examples

1. Case 1: Enzyme Inhibition
   A patient stabilized on theophylline (a CYP1A2 substrate) is prescribed ciprofloxacin (a strong CYP1A2 inhibitor) for a urinary tract infection. What is the likely outcome?
   Solution:
   1. Identify the mechanism: Ciprofloxacin inhibits the enzyme responsible for metabolizing theophylline.
   2. Determine the effect: Inhibition leads to decreased clearance and increased serum levels of theophylline.
   3. Clinical Result: The patient is at a high risk for theophylline toxicity (nausea, tremors, seizures).
2. Case 2: Pharmacodynamic Synergy
   A patient takes lisinopril for hypertension and is started on spironolactone for heart failure. What electrolyte abnormality should the pharmacist monitor?
   Solution:
   1. Identify the drugs: Lisinopril (ACE inhibitor) and spironolactone (Aldosterone antagonist).
   2. Mechanism: Both drugs reduce potassium excretion in the distal tubule/collecting duct.
   3. Clinical Result: Additive risk of hyperkalemia. Monitor serum potassium levels frequently.
3. Case 3: Chelation Interaction
   A patient is taking levothyroxine for hypothyroidism and begins taking an over-the-counter calcium carbonate supplement for bone health at the same time every morning. What happens to the TSH level?
   Solution:
   1. Identify the mechanism: Divalent cations like calcium chelate levothyroxine in the GI tract.
   2. Effect: This reduces the absorption of levothyroxine.
   3. Clinical Result: Lower levothyroxine absorption leads to a hypothyroid state, causing the TSH level to increase.

Practice Questions

1. A 65-year-old male with atrial fibrillation is taking warfarin. He is started on amiodarone for rhythm control. How should the warfarin dose be adjusted?
2. A patient with HIV is taking a regimen containing ritonavir. He is now prescribed simvastatin for hyperlipidemia. Is this combination appropriate?
3. A patient taking phenelzine (an MAOI) consumes a large meal containing aged cheeses and red wine. What acute medical emergency might occur?

4. A patient on lithium for bipolar disorder is started on hydrochlorothiazide for hypertension. What is the effect on the lithium concentration?
5. A patient is taking rifampin for tuberculosis and is also on an oral contraceptive (ethinyl estradiol/norethindrone). What counseling point is most critical?
6. A patient with chronic pain takes methadone and is prescribed erythromycin for a skin infection. What cardiac monitoring is necessary?
7. A transplant patient on cyclosporine is started on St. John's Wort by a friend's recommendation. What is the risk regarding the transplant?
8. A patient with depression taking sertraline is prescribed tramadol for acute pain. What syndrome should the pharmacist monitor for?
9. An elderly patient is taking digoxin for heart failure. The physician adds clarithromycin to treat community-acquired pneumonia. What happens to the digoxin level?
10. A patient is taking sildenafil for erectile dysfunction. He experiences chest pain and is given sublingual nitroglycerin. What is the primary concern?

Answers & Explanations

1. Answer: Decrease warfarin dose by 30-50%. Amiodarone is a potent inhibitor of CYP2C9, the primary enzyme that metabolizes the more potent S-enantiomer of warfarin. Adding amiodarone will significantly increase the INR, raising the risk of bleeding.
2. Answer: No, the combination is contraindicated. Ritonavir is a strong CYP3A4 inhibitor. Simvastatin is a major CYP3A4 substrate. This interaction dramatically increases simvastatin levels, significantly raising the risk of myopathy and rhabdomyolysis.
3. Answer: Hypertensive Crisis. MAOIs prevent the breakdown of tyramine. Aged cheeses and wine are high in tyramine. This leads to a massive release of norepinephrine, causing a dangerous increase in blood pressure.
4. Answer: Lithium levels will increase. Thiazide diuretics cause sodium depletion. The kidneys compensate by reabsorbing sodium in the proximal tubule, and since lithium is handled similarly to sodium, lithium reabsorption also increases, potentially leading to toxicity.
5. Answer: Use a back-up (non-hormonal) method of contraception. Rifampin is a potent inducer of CYP3A4, which increases the metabolism of estrogen and progestin, rendering the oral contraceptive ineffective. This is a common topic in NAPLEX Infectious Disease Practice Questions.
6. Answer: Monitor for QTc prolongation via EKG. Both methadone and erythromycin are known to prolong the QT interval. Their combined use increases the risk of Torsades de Pointes.
7. Answer: Risk of organ rejection. St. John's Wort is a potent inducer of CYP3A4 and P-gp. This will significantly decrease cyclosporine concentrations to sub-therapeutic levels.
8. Answer: Serotonin Syndrome. Both sertraline (SSRI) and tramadol have serotonergic activity. Combining them increases the risk of serotonin syndrome, characterized by mental status changes, autonomic instability, and neuromuscular hyperactivity.
9. Answer: Digoxin levels will increase. Clarithromycin inhibits P-glycoprotein (P-gp). Digoxin is a P-gp substrate. Inhibition of P-gp in the gut and kidneys leads to increased absorption and decreased excretion of digoxin.
10. Answer: Severe, fatal hypotension. Nitrates and PDE-5 inhibitors both increase cyclic GMP levels through different pathways (nitrates increase production, PDE-5 inhibitors decrease breakdown). This leads to profound vasodilation that can be life-threatening.

1. Which of the following is a potent CYP450 inducer that can decrease the efficacy of many medications?

• AAmiodarone
• BRifampin
• CKetoconazole
• DErythromycin

Frequently Asked Questions

What is the difference between a CYP450 inducer and inhibitor?

An inhibitor slows down enzyme activity, leading to higher levels of the substrate drug and increased toxicity risk. An inducer speeds up enzyme production or activity, leading to lower levels of the substrate drug and potential therapeutic failure.

How does P-glycoprotein (P-gp) affect drug interactions?

P-gp is an efflux pump that moves drugs out of cells, particularly in the gut and kidneys. Inhibiting P-gp increases drug absorption and decreases excretion, whereas inducing P-gp reduces the amount of drug that reaches the systemic circulation.

Why are narrow therapeutic index (NTI) drugs more susceptible to interactions?

NTI drugs like warfarin, digoxin, and lithium have a very small window between a therapeutic dose and a toxic dose. Even minor pharmacokinetic changes caused by a drug interaction can push the patient into a toxic or sub-therapeutic range.

What is a "washout period" in the context of drug interactions?

A washout period is the time required for a drug to be completely eliminated from the body before starting a new, interacting medication. This is most critical when switching between MAOIs and SSRIs to prevent serotonin syndrome.

Can food significantly impact drug metabolism?

Yes, food can act as an enzyme inhibitor, such as grapefruit juice inhibiting CYP3A4, or provide substrates like tyramine in aged foods that cause dangerous reactions with MAOIs. Additionally, minerals in food can chelate drugs like tetracyclines.